Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

about

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

Item

http://www.wikidata.org/entity/Q47936579

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

@en

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

@nl

type

Item

label

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

@en

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

@nl

prefLabel

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

@en

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

@nl

P1476

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

@en

P2093

Cecilia Bosco

http://www.w3.org/2001/XMLSchema#string

Chloe Wong

http://www.w3.org/2001/XMLSchema#string

Danielle Crawley

http://www.w3.org/2001/XMLSchema#string

Niklas Hammar

http://www.w3.org/2001/XMLSchema#string

Pär Stattin

http://www.w3.org/2001/XMLSchema#string

P2860

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Maternal pesticide exposure from multiple sources and selected congenital anomalies.

An investigation into the relationship between statins and cancer using population-based data.

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.

NCCN clinical practice guidelines in oncology: prostate cancer.

Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base--a refined prostate cancer trajectory.

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

P304

260-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJU.14023

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28940667

http://www.w3.org/2001/XMLSchema#string